Search results
Showing 46 to 60 of 104 results for melanoma
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.
vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma. Any explanatory notes(if applicable) This may...
Question Vitamin D supplementation: In people with stage I to III melanoma does vitamin D supplementation improve overall survival? This...
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over (NG36)
This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 or over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. The guideline aims to reduce variation in practice and improve survival.
See a complete list of all our guidance and quality standards currently open for consultation
Lifileucel for previously treated unresectable or metastatic melanoma ID3863: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 22 January 2026.
Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.
Discontinued Reference number: GID-IP1041
analysis of melanoma tissue samples. Full details of the evidence and the committee's discussion are in evidence review A: genetic...
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]
Awaiting development Reference number: GID-TA11881 Expected publication date: TBC
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]
Discontinued Reference number: GID-TA10330
Temozolomide for the treatment of advanced and metastatic melanoma [ID316]
Discontinued Reference number: GID-TAG401
Awaiting development Reference number: GID-TA11882 Expected publication date: TBC